Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Locally advanced rectal cancer (T3, T4 or lymph node positive tumors) are conventionally
treated with 5FU / capecitabine based chemoradiation prior to surgical resection. This
treatment is associated with only a 15-20% pathological complete response. Selinexor
(KPT-330) is a Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist that has
demonstrated radiosensitization with in vivo models and has suggested single agent activity
against colorectal cancers in a Phase I trial. Here we perform a Phase I/Ib trial of standard
chemoradiation combined with Selinexor.
We hypothesize that tumors treated with this new combination will demonstrate an increased
response rate compared to those treated with capecitabine-radiation alone.